相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
2
100.0%
暂无批准数据
- Harrow has reintroduced VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% to the U.S. market, the first and only FDA-approved topical immunomodulator for pediatric VKC. - VKC is a chronic, potentially sight-threatening allergic eye disease primarily affecting children, with approximately 61% of patients inadequately controlled on antihistamines alone. - VERKAZIA targets underlying inflammatory mechanisms without the risks of glaucoma or cataract formation associated with chronic corticosteroid use. - The re-launch is supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability to ensure dependable supply.
- The FDA issued a complete response letter to Sydnexis for SYD-101, a 0.01% atropine formulation designed to slow pediatric myopia progression, despite the Phase 3 STAR trial meeting its primary efficacy endpoint. - The agency acknowledged the primary efficacy goal was achieved but concluded the evidence did not demonstrate effectiveness of low-dose atropine for treating myopia in children, with no safety or quality deficiencies identified. - SYD-101 received European Commission marketing authorization in June 2025 and is marketed as Ryjunea by Santen across Europe, Middle East, and Africa. - Pediatric progressive myopia affects nearly one-third of children worldwide, with prevalence projected to exceed 740 million cases by 2050, yet no FDA-approved pharmaceutical options currently exist in the United States.
- The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP). - Advancements like sustained-release implants and micro-dosing technologies are enhancing patient compliance and improving outcomes in ocular hypertension treatment. - Enhanced imaging techniques, such as optical coherence tomography (OCT), facilitate early diagnosis and intervention, contributing to the growth of the ocular hypertension market. - Over 60 companies are actively developing more than 70 pipeline drugs for ocular hypertension, signaling robust innovation and future growth potential in the domain.
